World Class Experts

Our core staff includes MDs, Allergists, PhDs, experienced clinical trial managers and a staff of 14 clinical research associates that focus solely on allergy clinical trials.

Mark B. Abelson MD, CM, FRCSC

Founder and Chairman

Dr. Abelson is a Clinical Professor of Ophthalmology at Harvard Medical School and Senior Scientist at the Massachusetts Eye and Ear Infirmary. During his 35+ years of experience in allergy research, Dr. Abelson has developed clinical models used for international approvals in both allergy and dry eye. His expertise includes regulatory interface, study execution, clinical strategies, and data interpretation.

Paul Gomes MS

Vice President, Allergy

Mr. Gomes has more than 17 years of experience in successfully executing allergy programs and providing clinical–regulatory strategy. He has overseen over 100 allergy clinical trials, published numerous articles on specific drugs, and helped approve six allergic conjunctivitis treatments. Mr. Gomes is generally regarded as one of the world’s experts in clinical strategy in allergy drug development and has presented on the topic for numerous biotech and pharmaceutical companies.

Keith Lane

Director, Rhinitis R+D

Mr. Lane has spent the past 10 years working on the identification and development of clinical models, with a special focus on sub-population response to allergic insult and therapeutic intervention. He led the team that developed controlled environments and has project managed all of the validation and verification studies to date related to our systems.

How it works

Allergen BioCube Infographic
Download a PDF »

Ora Model Based protocols are optimized to decrease timelines to regulatory filings and the ultimate increased costs result in a product that is generating revenue potentially years before traditional studies are completed.